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Summary
Background Lowering of LDL cholesterol with standard statin regimens reduces the risk of occlusive vascular events 
in a wide range of individuals. We aimed to assess the safety and eﬃ  cacy of more intensive lowering of LDL cholesterol 
with statin therapy.
Methods We undertook meta-analyses of individual participant data from randomised trials involving at least 
1000 participants and at least 2 years’ treatment duration of more versus less intensive statin regimens (ﬁ ve trials; 
39 612 individuals; median follow-up 5·1 years) and of statin versus control (21 trials; 129 526 individuals; median 
follow-up 4·8 years). For each type of trial, we calculated not only the average risk reduction, but also the average risk 
reduction per 1·0 mmol/L LDL cholesterol reduction at 1 year after randomisation.
Findings In the trials of more versus less intensive statin therapy, the weighted mean further reduction in LDL 
cholesterol at 1 year was 0·51 mmol/L. Compared with less intensive regimens, more intensive regimens produced 
a highly signiﬁ cant 15% (95% CI 11–18; p<0·0001) further reduction in major vascular events, consisting of 
separately signiﬁ cant reductions in coronary death or non-fatal myocardial infarction of 13% (95% CI 7–19; 
p<0·0001), in coronary revascularisation of 19% (95% CI 15–24; p<0·0001), and in ischaemic stroke of 16% (95% 
CI 5–26; p=0·005). Per 1·0 mmol/L reduction in LDL cholesterol, these further reductions in risk were similar to 
the proportional reductions in the trials of statin versus control. When both types of trial were combined, similar 
proportional reductions in major vascular events per 1·0 mmol/L LDL cholesterol reduction were found in all 
types of patient studied (rate ratio [RR] 0·78, 95% CI 0·76–0·80; p<0·0001), including those with LDL cholesterol 
lower than 2 mmol/L on the less intensive or control regimen. Across all 26 trials, all-cause mortality was reduced 
by 10% per 1·0 mmol/L LDL reduction (RR 0·90, 95% CI 0·87–0·93; p<0·0001), largely reﬂ ecting signiﬁ cant 
reductions in deaths due to coronary heart disease (RR 0·80, 99% CI 0·74–0·87; p<0·0001) and other cardiac 
causes (RR 0·89, 99% CI 0·81–0·98; p=0·002), with no signiﬁ cant eﬀ ect on deaths due to stroke (RR 0·96, 95% CI 
0·84–1·09; p=0·5) or other vascular causes (RR 0·98, 99% CI 0·81–1·18; p=0·8). No signiﬁ cant eﬀ ects were 
observed on deaths due to cancer or other non-vascular causes (RR 0·97, 95% CI 0·92–1·03; p=0·3) or on cancer 
incidence (RR 1·00, 95% CI 0·96–1·04; p=0·9), even at low LDL cholesterol concentrations.
Interpretation Further reductions in LDL cholesterol safely produce deﬁ nite further reductions in the incidence 
of heart attack, of revascularisation, and of ischaemic stroke, with each 1·0 mmol/L reduction reducing the 
annual rate of these major vascular events by just over a ﬁ fth. There was no evidence of any threshold within the 
cholesterol range studied, suggesting that reduction of LDL cholesterol by 2–3 mmol/L would reduce risk by 
about 40–50%. 
Funding UK Medical Research Council, British Heart Foundation, European Community Biomed Programme, 
Australian National Health and Medical Research Council, and National Heart Foundation.
Introduction
The Cholesterol Treatment Trialists’ (CTT) Collaboration 
previously reported a meta-analysis1 of individual data 
from 90 000 individuals in 14 randomised trials2–15 of statin 
therapy versus control. Allocation to the statin regimens 
in those trials resulted in a weighted mean diﬀ erence of 
about 1·0 mmol/L in LDL cholesterol and a proportional 
reduction of about a ﬁ fth in major vascular events (deﬁ ned 
as coronary death, non-fatal myocardial infarction, 
coronary revascularisation, or stroke). Observational 
studies show that there is a continuous positive relation 
between coronary disease risk and blood cholesterol 
concentrations,16–18 so larger reductions in LDL cholesterol 
might well produce larger reductions in risk. This 
hypothesis is indirectly supported by the positive 
association identiﬁ ed in the previous meta-analysis 
between the absolute reduction in LDL cholesterol in a 
trial and the proportional reduction in major vascular 
events in that trial.1 
Standard statin regimens (eg, 20–40 mg simvastatin 
daily) typically reduce LDL cholesterol concentrations by 
about a third, but regimens involving higher doses or 
newer, more potent statins (eg, 40–80 mg atorvastatin or 
10–20 mg rosuvastatin daily) can halve LDL cholesterol.19–22 
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To determine whether larger reductions in LDL cholesterol 
safely produce further reductions in major vascular events, 
several trials have compared more intensive versus 
standard statin regimens.23–27 Although their results tend to 
suggest further beneﬁ t,28 only two had signiﬁ cant results 
for their primary outcome.24,26 The present meta-analysis of 
individual data from all of these trials assesses the eﬀ ects 
of more intensive statin therapy more reliably than before. 
Several recent trials of statin therapy in patients with renal 
failure29,30 or chronic heart failure31,32 have not shown clear 
evidence of beneﬁ t, and in our meta-analysis we also 
investigate those ﬁ ndings. Moreover, we address the 
question of whether lowering of LDL cholesterol to very 
low concentrations might have adverse consequences.18,33–35
Methods
Study eligibility and outcomes
The CTT protocol was agreed before the ﬁ rst trial results 
were available.36 In this second cycle of analyses, we 
aimed to include all eligible trials reported by the end 
of 2009. Trials were eligible for inclusion if: the main 
eﬀ ect of the intervention was to lower LDL cholesterol; 
no other diﬀ erences in risk factor modiﬁ cation were 
intended; and at least 1000 participants were to be 
recruited with at least 2 years’ scheduled treatment 
duration. 
Prespeciﬁ ed outcomes were cause-speciﬁ c mortality, 
major coronary event (coronary death or non-fatal 
myocardial infarction), coronary revascularisation 
(angioplasty or bypass grafting), stroke (subdivided by 
type), and new cancer diagnosis (subdivided by site).36 As 
in the ﬁ rst cycle of meta-analyses,1 a major vascular event 
was deﬁ ned as the ﬁ rst occurrence of any major coronary 
event, coronary revascularisation, or stroke. In trials in 
patients with acute coronary syndrome,23,24 many of the 
revascularisation procedures had been planned before 
trial entry and happened soon afterwards, so the masked 
treatment allocation could not aﬀ ect them. Consequently, 
only procedures resulting from recurrent ischaemia23 or 
occurring more than 30 days after randomisation24 
(depending on the trial) were included. For the present 
analyses, cardiac deaths were subdivided into those 
probably or deﬁ nitely due to coronary disease and those 
that might not have been (eg, sudden deaths or deaths 
attributed to arrhythmia, heart failure, or unspeciﬁ ed 
cardiac causes). As a result, the 14 trials that were 
included in the previous report1 now involve slightly 
fewer major coronary and major vascular events than 
they did before.
Statistical analysis
Analyses were to include all randomised patients 
irrespective of whether they received their allocated 
treatment (intention to treat). The primary meta-analyses 
were of the eﬀ ects on disease event rates in each trial 
calculated as the logrank (o–e) and its variance (v) for ﬁ rst 
events weighted by the absolute LDL cholesterol diﬀ erence 
in that trial at 1 year (d mmol/L),36 and are reported as 
eﬀ ects per 1·0 mmol/L reduction in LDL cholesterol. In a 
meta-analysis of several trials, the log of the rate ratio per 
mmol/L (log RR) is calculated as S/V with variance 1/V 
(and hence with 95% CI of S/V±1·96/√V), where S is the 
sum over all trials of d (o–e) and V is the sum over all trials 
of d²v. (For unweighted analyses, d is omitted from these 
formulae.) For most subgroup analyses, the weight for a 
particular subgroup was the LDL cholesterol diﬀ erence 
observed in the whole trial, but analyses by baseline LDL 
cholesterol concentration used trial- and subgroup-
speciﬁ c LDL weights. In trials comparing more versus 
less intensive statin therapy, the relevant baseline lipid 
values would be those achieved on the less intensive 
regimen. In three of these trials,23–25 however, any statin 
therapy was stopped before randomisation, so their 
relevant baseline values had to be estimated by multiplying 
the values at the randomisation visit (ie, oﬀ  statin 
treatment) by the mean proportional reduction observed 
at 1 year among those allocated the less intensive regimen. 
Proportional risk reductions in diﬀ erent subgroups were 
compared by standard χ² tests for heterogeneity or, where 
appropriate, trend. To help to allow for multiple 
subdivisions, only summary rate ratios have 95% CIs; all 
other rate ratios have 99% CIs. Analyses were done with 
SAS version 9.1 (SAS Institute, Cary) and R version 2.11.1 
(www.R-project.org).
Role of the funding sources
The funding sources had no involvement in study 
design, data collection, analysis, interpretation, report 
writing or publication. The writing committee had full 
access to all data and accepts full responsibility for the 
content of this report. 
Results
For the meta-analyses of more versus less intensive statin 
therapy, individual participant data were available from all 
ﬁ ve eligible trials: two23,24 in 8659 patients with acute 
coronary syndrome and three in 30 953 patients with stable 
coronary disease25–27 (table; webappendix pp 1 and 2). 
Overall, among the 39 612 participants in these ﬁ ve trials, 
the weighted mean baseline LDL cholesterol concentration 
was estimated to be 2·53 mmol/L, the weighted mean 
diﬀ erence at one year was 0·51 mmol/L, and the weighted 
median follow-up duration among survivors was 5·1 years 
(2·1 years for patients with acute coronary syndrome and 
5·8 years for those with stable disease). 
The previous CTT meta-analysis of statin therapy versus 
control involved 14 trials in 90 056 participants.1 For this 
second cycle, individual participant data were available 
from seven more trials29–31,37–40 of statin versus control 
among 39 470 participants: two in primary prevention,37,38 
two in haemodialysis patients,29,30 and one each in patients 
with coronary disease,39 diabetes,40 and heart failure31 
(table; webappendix pp 1 and 2). Overall, among the 
129 526 participants in these 21 trials, the weighted mean 
See Online for webappendix
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baseline LDL cholesterol concentration was 3·70 mmol/L, 
the weighted mean diﬀ erence at 1 year was 1·07 mmol/L, 
and the weighted median follow-up duration in survivors 
was 4·8 years. Individual participant data were unavailable 
from three eligible trials involving 11 342 patients: 
CORONA,32 SPARCL,33 and GREACE.41
First major vascular events were recorded in the ﬁ ve 
trials of more versus less intensive statin therapy 
in 3837 (4·5% per annum) of 19 829 participants 
allocated more intensive versus 4416 (5·3% per annum) 
of 19 783 allocated less intensive therapy (ﬁ gure 1), 
corresponding to a highly signiﬁ cant further 
Number of 
patients
Treatment 
comparison (mg 
per day)
Median 
follow–up 
in survivors 
(years)*
Baseline 
LDL-C 
(mmol/L)
LDL-C 
diﬀ erence at 
1 year  
(mmol/L)
Women (%) Diabetes (%) Prior CHD (%) Other vascular 
disease (%)†
No prior 
vascular 
disease (%)‡
More versus less statin
PROVE–IT 4162 A80 vs P40 2·1 2·62§ –0·65 911 (22%) 734 (18%) 4162 (100%) 328 (8%) 0
A to Z 4497 S40 then S80 vs 
placebo then S20
2·0 2·09§ –0·30 1100 (24%) 1059 (24%) 4497 (100%) 479 (11%) 0
TNT 10 001 A80 vs A10 5·0 2·52 –0·62 1902 (19%) 1501 (15%) 10 001 (100%) 1537 (15%) 0
IDEAL 8888 A40–80 vs S20–40 4·8 2·64§ –0·55 1702 (19%) 1069 (12%) 8888 (100%) 971 (11%) 0
SEARCH 12 064 S80 vs S20 7·0 2·50 –0·39 2052 (17%) 1267 (11%) 12 064 (100%) 1062 (9%) 0
Subtotal (5 trials) 39 612 NA 5·1|| 2·53|| –0·51|| 7667 (19%) 5630 (14%) 39 612 (100%) 4377 (11%) 0
Statin versus control
SSSS 4444 S20–40 vs placebo 5·4 4·88 –1·77 827 (19%) 202 (5%) 4444 (100%) 126 (3%) 0
WOSCOPS 6595 P40 vs placebo 4·8 4·96 –1·07 0 76 (1%) 338 (5%) 193 (3%) 6096 (92%)
CARE 4159 P40 vs placebo 5·0 3·58 –1·03 576 (14%) 586 (14%) 4159 (100%) 0 0
Post–CABG 1351 L40–80 vs L2·5–5 4·3 4·02 –1·07 102 (8%) 116 (9%) 1351 (100%) 37 (3%) 0
AFCAPS/TexCAPS 6605 L20–40 vs placebo 5·2 3·89 –0·94 997 (15%) 155 (2%) 10 (<1%) 9 (<1%) 6586 (>99%)
LIPID 9014 P40 vs placebo 6·0 3·88 –1·03 1516 (17%) 782 (9%) 9014 (100%) 905 (10%) 0
GISSI–P 4271 P20 vs no treatment 2·0 3·92 –0·35 587 (14%) 582 (14%) 4271 (100%) 179 (4%) 0
LIPS 1677 F80 vs placebo 3·9 3·42 –0·92 271 (16%) 202 (12%) 1677 (100%) 142 (8%) 0 
HPS 20 536 S40 vs placebo 5·4 3·38 –1·29 5082 (25%) 5963 (29%) 13 386 (65%) 8865 (43%) 3161 (15%)
PROSPER 5804 P40 vs placebo 3·3 3·79 –1·04 3000 (52%) 623 (11%) 1881 (32%) 1026 (18%) 3254 (56%)
ALLHAT–LLT 10 355 P40 vs usual care 4·9 3·76 –0·54 5051 (49%) 3638 (35%) 1188 (11%) 1788 (17%) 8037 (78%)
ASCOT–LLA 10 305 A10 vs placebo 3·3 3·44 –1·07 1942 (19%) 2527 (25%) 15 (<1%) 1435 (14%) 8860 (86%)
ALERT 2102 F40 vs placebo 5·5 4·14 –0·84 715 (34%) 396 (19%) 400 (19%) 241 (11%) 1702 (81%)
CARDS 2838 A10 vs placebo 4·1 3·03 –1·14 909 (32%) 2838 (100%) 9 (<1%) 97 (3%) 2738 (96%)
ALLIANCE** 2442 A10–80 vs usual care 4·7 3·80 –1·16 434 (18%) 540 (22%) 2442 (100%) 162 (7%) 0
4D** 1255 A20 vs placebo 4·0 3·25 –0·89 578 (46%) 1255 (100%) 630 (50%) 666 (53%) 344 (27%)
ASPEN** 2410 A10 vs placebo 4·0 2·93 –0·99 811 (34%) 2410 (100%) 578 (24%) 302 (13%) 1663 (69%)
MEGA**†† 8214 P10–20 vs usual care 5·0 4·05 –0·67 5547 (68%) 1686 (21%) 42 (<1%) 53 (<1%) 8119 (99%)
JUPITER** 17 802 R20 vs placebo 2·0 2·70 –1·09 6801 (38%) 76 (<1%) 0 0 17 802 (100%)
GISSI–HF** 4574 R10 vs placebo 4·2 3·06 –0·92 1032 (23%) 1196 (26%) 1797 (39%) 4574 (100%) 0
AURORA** 2773 R10 vs placebo 4·6 2·58 –0·99 1050 (38%) 731 (26%) 659 (24%) 743 (27%) 1663 (60%)
Subtotal (21 trials) 129 526 NA 4·8|| 3·70|| –1·07|| 37 828 (29%) 26 580 (21%) 48 291 (37%) 21 543 (17%) 70 025 (54%)
Total (26 trials) 169 138 NA 4·9|| NA NA 45 495 (27%) 32 210 (19%) 87 903 (52%) 25 920 (15%) 70 025 (41%)
LDL-C=LDL-cholesterol. CHD=coronary heart disease. PROVE-IT=Pravastatin or Atorvastatin Evaluation and Infection Therapy.24 A=atorvastatin. P=pravastatin. A to Z=Aggrastat to Zocor.23 S=simvastatin. 
TNT=Treating to New Targets.26 IDEAL=Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group.25 SEARCH=Study of the Eﬀ ectiveness of Additional Reductions in Cholesterol and 
Homocysteine.27 SSSS=Scandinavian Simvastatin Survival Study.2 WOSCOPS=West of Scotland Coronary Prevention Study.3 CARE=Cholesterol And Recurrent Events.4 Post-CABG=Post-Coronary Artery Bypass Graft.5 
L=lovastatin. AFCAPS/TexCAPS=Air Force/Texas Coronary Atherosclerosis Prevention Study.6 LIPID=Long–term Intervention with Pravastatin in Ischaemic Disease.7 GISSI–P=Gruppo Italiano per lo Studio della 
Sopravvivenza nell’Infarto Miocardico.8 LIPS=Lescol Intervention Prevention Study.9 F=ﬂ uvastatin. HPS=Heart Protection Study.10 PROSPER=PROspective Study of Pravastatin in the Elderly at Risk.11 ALLHAT-
LLT=Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.12 ASCOT-LLA=Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm.13 ALERT=Assessment of Lescol in Renal 
Transplantation.14 CARDS=Collaborative Atorvastatin Diabetes Study.15 ALLIANCE=Aggressive Lipid-Lowering Initiation Abates New Cardiac Events.39 4D=Die Deutsche Diabetes Dialyse Studie.29 ASPEN=Atorvastatin 
Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus.40 MEGA=Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese Study 
Group.37 JUPITER=Justiﬁ cation for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin study group.38 R=rosuvastatin. GISSI-HF=Gruppo Italiano per lo Studio della Sopravvivenza 
nell’Insuﬃ  cienza cardiac.31 AURORA=A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events.30  *Estimated with standard Kaplan-Meier 
methods, with patients censored at their date of death. †History of intracerebral bleed, transient ischaemic attack, ischaemic stroke, unknown stroke, peripheral artery disease, or heart failure (if known). ‡No known 
history of CHD or other vascular disease. §These three trials did not have active run–in periods; the values shown are the estimated on-treatment LDL cholesterol levels in the standard statin group. ||Median follow–
up, baseline LDL-C, and LDL-C diﬀ erence at 1 year weighted by trial–speciﬁ c variances of observed logrank (o–e) for major vascular events. **Additional statin versus control trials included in this second cycle of 
analyses. ††Includes 382 randomised patients who were excluded from the original publication.37
Table: Baseline characteristics and eligibility criteria of participating trials
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proportional risk reduction of 15% (95% CI 11–18; 
p<0·0001) associated with the mean 0·51 mmol/L 
further LDL cholesterol reduction. In comparisons 
between these ﬁ ve trials, larger absolute reductions in 
LDL cholesterol were associated with larger proportional 
risk reductions (trend p=0·0004), but there was little 
residual variation after adjustment for LDL cholesterol 
diﬀ erences (trend p=0·05). Overall, the weighted 
average further reduction in ﬁ rst major vascular events 
was 28% (95% CI 22–34; p<0·0001) per 1·0 mmol/L 
reduction in LDL cholesterol (ﬁ gure 1), with separately 
signiﬁ cant reductions in each of the major components 
of this composite outcome (ﬁ gure 2).
In the updated meta-analysis of 21 trials of statin 
versus control, 7136 (2·8% per annum) of 
64 744 participants allocated statin therapy had ﬁ rst 
major vascular events versus 8934 (3·6% per annum) of 
64 782 allocated control (ﬁ gure 1), corresponding to a 
highly signiﬁ cant 22% (95% CI 19–24; p<0·0001) risk 
reduction with a 1·07 mmol/L LDL cholesterol 
reduction. In comparisons between these 21 trials, 
larger absolute reductions in LDL cholesterol were 
Figure 1: Eﬀ ects on any major vascular event in each study 
In the left panel, unweighted rate ratios (RRs) for each trial of the comparison of ﬁ rst event rates between randomly allocated treatment groups are plotted along with 99% CIs. Trials are ordered 
according to the absolute reduction in LDL cholesterol (LDL-C) at 1 year within each type of trial comparison (more vs less statin and statin vs control). In the right panel, rate ratios are weighted per 
1·0 mmol/L LDL cholesterol diﬀ erence at 1 year. Subtotals and totals with 95% CIs are shown by open diamonds. 
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(mmol/L)
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0·79 (0·77−0·81)
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0·78 (0·76−0·80)
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Trend: χ21=0·6
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Trend: χ21=12·4
(p=0·0004)
Heterogeneity between statin vs control and more vs less:
− before taking account of LDL diﬀerences: χ21=10·7 (p=0·001)
− after taking account of LDL diﬀerences: χ21=4·5 (p=0·03)
Control/less betterStatin/more better Control/less betterStatin/more better
406 (11·3%)
889 (4·0%)
938 (5·2%)
1347 (3·6%)
257 (7·2%)
3837/19 829
       (4·5%)
555 (5·4%)
1511 (3·1%)
254 (5·4%)
81 (1·5%)
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79 (3·0%)
232 (1·5%)
431 (4·9%)
433 (4·8%)
936 (4·1%)
114 (2·7%)
362 (8·1%)
143 (0·8%)
164 (6·9%)
172 (2·2%)
144 (9·0%)
135 (2·7%)
102 (0·5%)
758 (3·3%)
208 (5·4%)
7136/64 744
       (2·8%)
10 973/84 573
          (3·2%)
458 (13·1%)
1164 (5·4%)
1106 (6·3%)
1406 (3·8%)
282 (8·1%)
4416/19 783
       (5·3%)
796 (8·2%)
2043 (4·3%)
293 (6·4%)
123 (2·4%)
194 (1·0%)
307 (1·9%)
100 (3·8%)
318 (2·1%)
495 (5·6%)
553 (6·3%)
1153 (5·2%)
136 (3·3%)
368 (8·3%)
201 (1·2%)
195 (9·0%)
174 (2·2%)
162 (10·1%)
140 (2·7%)
 140 (0·7%)
812 (3·5%)
231 (6·1%)
8934/64 782
       (3·6%)
13 350/84 565
         (4·0%)
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associated with larger proportional reductions in risk 
(trend p<0·0001), but no signiﬁ cant residual variation 
remained after adjustment for LDL cholesterol 
diﬀ erences (trend p=0·4). Overall, the weighted average 
reduction in major vascular events was 21% (95% CI 
19–23; p<0·0001) per 1·0 mmol/L reduction in LDL 
cholesterol (ﬁ gures 1 and 2). 
After diﬀ erences in the absolute reductions in LDL 
cholesterol were accounted for, the proportional 
reduction in the incidence of major vascular events per 
mmol/L was slightly larger (heterogeneity p=0·03; 
ﬁ gure 1) in the trials of more versus less intensive 
therapy than in those of statin versus control. Taking all 
26 trials together, the risk reduction was 22% (95% CI 
20–24; p<0·0001) per 1·0 mmol/L reduction in LDL 
cholesterol at 1 year, with a signiﬁ cant 12% reduction 
during the ﬁ rst year after randomisation (p<0·0001) and 
highly signiﬁ cant reductions of about a quarter during 
each subsequent year (all p<0·0001; webappendix p 3). 
First major coronary events were recorded in the ﬁ ve 
trials of more versus less intensive statin therapy in 
1725 (1·9% per annum) participants allocated more 
intensive versus 1973 (2·2% per annum) allocated less 
intensive therapy (ﬁ gure 2). This highly signiﬁ cant further 
risk reduction of 13% (95% CI 7–19; p<0·0001) represented 
a signiﬁ cant reduction in non-fatal myocardial infarction 
of 15% (99% CI 6–24; p<0·0001) and a non-signiﬁ cant 
reduction in coronary death of 7% (p=0·2). The 
Figure 2: Eﬀ ects on each type of major vascular event 
In the left panel, unweighted rate ratios (RRs) are plotted for each comparison of ﬁ rst event rates between randomly allocated treatment groups. In the right panel, RRs are weighted per 1·0 mmol/L 
LDL cholesterol (LDL-C) diﬀ erence at 1 year. RRs are shown with horizontal lines denoting 99% CIs or with open diamonds denoting 95% CIs. MI=myocardial infarction. CHD=coronary heart disease. 
CABG=coronary artery bypass graft. PTCA=percutaneous transluminal coronary angioplasty. 
More vs less statin (ﬁve trials: 0·51 mmol/L LDL diﬀerence)
Non-fatal MI
CHD death
Any major coronary event
CABG
PTCA
Unspeciﬁed
Any coronary revascularisation
Ischaemic stroke
Haemorrhagic stroke
Unknown stroke
Any stroke
Five trials: any major vascular event
Statin vs control (21 trials: 1·07 mmol/L LDL diﬀerence)
Non-fatal MI
CHD death
Any major coronary event
CABG
PTCA
Unspeciﬁed
Any coronary revascularisation
Ischaemic stroke
Haemorrhagic stroke
Unknown stroke
Any stroke
21 trials: any major vascular event
All 26 trials: any major vascular event
0·5 0·75 1 1·25 1·5
0·71 (0·58−0·87)
0·85 (0·63−1·15)
0·74 (0·65−0·85)
p<0·0001
0·72 (0·55−0·95)
0·60 (0·50−0·71)
0·78 (0·58−1·04)
0·66 (0·60−0·73)
p<0·0001
0·69 (0·50−0·95)
1·39 (0·57−3·39)
0·63 (0·24−1·66)
0·74 (0·59−0·92)
p=0·007
0·72 (0·66−0·78)
p<0·0001
0·74 (0·69−0·78)
0·80 (0·73−0·86)
0·76 (0·73−0·79)
p<0·0001
0·76 (0·69−0·83)
0·78 (0·69−0·89)
0·76 (0·70−0·83)
0·76 (0·73−0·80)
p<0·0001
0·80 (0·73−0·88)
1·10 (0·86−1·42)
0·88 (0·76−1·02)
0·85 (0·80−0·90)
p<0·0001
0·79 (0·77−0·81)
p<0·0001
0·78 (0·76−0·80)
p<0·0001
0·5 0·75 1 1·25 1·5
Control/less betterStatin/more better Control/less betterStatin/more better
0·85 (0·76−0·94)
0·93 (0·81−1·07)
0·87 (0·81−0·93)
p<0·0001
0·86 (0·75−0·99)
0·76 (0·69−0·84)
0·87 (0·74−1·03)
0·81 (0·76−0·85)
p<0·0001
0·84 (0·71−0·99)
1·21 (0·76−1·91)
0·79 (0·51−1·21)
0·86 (0·77−0·96)
p=0·009
0·85 (0·82−0·89)
p<0·0001
0·71 (0·66−0·76)
0·78 (0·71−0·86)
0·73 (0·70−0·77)
p<0·0001
0·71 (0·63−0·80)
0·76 (0·66−0·87)
0·77 (0·71−0·83)
0·75 (0·72−0·79)
p<0·0001
0·80 (0·72−0·89)
1·15 (0·87−1·51)
0·88 (0·76−1·02)
0·85 (0·80−0·91)
p<0·0001
0·78 (0·76−0·81)
p<0·0001
 1175 (1·3%)
645 (0·7%)
1725 (1·9%)
637 (0·7%)
1166 (1·3%)
447 (0·5%)
2250 (2·6%)
440 (0·5%)
69 (0·1%)
63 (0·1%)
572 (0·6%)
3837 (4·5%)
2310 (0·9%)
1242 (0·5%)
3380 (1·3%)
816 (0·3%)
601 (0·2%)
1686 (0·6%)
3103 (1·2%)
987 (0·4%)
188 (0·1%)
555 (0·2%)
1730 (0·7%)
7136 (2·8%)
10 973 (3·2%)
 1380 (1·5%)
694 (0·7%)
1973 (2·2%)
731 (0·9%)
1508 (1·8%)
502 (0·6%)
2741 (3·2%)
526 (0·6%)
57 (0·1%)
80 (0·1%)
663 (0·7%)
4416 (5·3%)
3213 (1·2%)
1587 (0·6%)
4539 (1·7%)
1126 (0·4%)
775 (0·3%)
2165 (0·8%)
4066 (1·6%)
1225 (0·5%)
163 (0·1%)
629 (0·2%)
2017 (0·8%)
8934 (3·6%)
13 350 (4·0%)
Events (% per annum)
Statin/more Control/less
RR (CI) per 1 mmol/L reduction in LDL-CUnweighted RR (CI)
99% or
95% CI
Articles
www.thelancet.com   Vol 376   November 13, 2010 1675
proportional reduction in the incidence of major coronary 
events per 1·0 mmol/L LDL cholesterol reduction was 
similar (heterogeneity p=0·8; ﬁ gure 2; webappendix p 4) 
in the trials of more versus less intensive therapy 
(26% reduction, 95% CI 15–35) and in those of statin 
versus control (24%, 95% CI 21–27). Taking all 26 trials 
together, the risk reduction was 24% (95% CI 22–27; 
p<0·0001) per 1·0 mmol/L reduction in LDL cholesterol, 
with highly signiﬁ cant reductions in non-fatal myocardial 
infarction of 27% (95% CI 23–30; p<0·0001; webappendix 
p 5) and in coronary death of 20% (95% CI 15–25; 
p<0·0001; webappendix p 6).
First coronary revascularisation procedures were 
recorded in the ﬁ ve trials of more versus less intensive 
statin therapy in 2250 (2·6% per annum) participants 
allocated more intensive versus 2741 (3·2% per annum) 
allocated less intensive therapy (ﬁ gure 2). This highly 
signiﬁ cant further risk reduction of 19% (95% CI 15–24; 
p<0·0001) represented signiﬁ cant reductions in coronary 
artery surgery of 14% (99% CI 1–25; p=0·005) and in 
coronary angioplasty of 24% (99% CI 16–31; p<0·0001). 
The proportional reduction in the incidence of coronary 
revascularisation per 1·0 mmol/L reduction in LDL 
cholesterol was signiﬁ cantly larger (heterogeneity p=0·01; 
ﬁ gure 2; webappendix p 7) in the trials of more versus less 
intensive therapy (34% reduction, 95% CI 27–40) than in 
those of statin versus control (24%, 95% CI 20–27). This 
signiﬁ cant heterogeneity reﬂ ected a larger eﬀ ect on 
coronary angioplasty and accounted for the observed 
diﬀ erence between these groups of trials in the 
proportional reduction in major vascular events. Taking 
all 26 trials together, the risk reduction was 25% (95% CI 
22–28; p<0·0001; webappendix p 7) per 1·0 mmol/L 
reduction in LDL cholesterol, with similar reductions in 
coronary artery surgery (25%, 99% CI 18–31) and in 
coronary angioplasty (28%, 99% CI 20–35).
First strokes of any type were recorded in the ﬁ ve trials 
of more versus less intensive statin therapy in 572 (0·6% 
per annum) participants allocated more intensive versus 
663 (0·7% per annum) allocated less intensive therapy 
(ﬁ gure 2). This signiﬁ cant further risk reduction of 14% 
(95% CI 4–23; p=0·009) represented a 16% (99% CI 
1–29) reduction in the risk of ischaemic stroke (440 vs 
526; risk ratio [RR] 0·84, 99% CI 0·71–0·99; p=0·005) 
and a non-signiﬁ cant excess of haemorrhagic stroke (69 
vs 57; RR 1·21, 99% CI 0·76–1·91; p=0·3). The 
proportional reduction in the incidence of stroke per 
1·0 mmol/L LDL cholesterol reduction was non-
signiﬁ cantly larger (heterogeneity p=0·2; ﬁ gure 2; 
webappendix p 8) in the trials of more versus less 
intensive statin therapy (26% reduction, 95% CI 8–41) 
than in those of statin versus control (15% reduction, 
95% CI 10–20). Taking all 26 trials together, the risk 
reduction was 16% (95% CI 11–21; p<0·0001; 
webappendix p 8) per 1·0 mmol/L LDL cholesterol 
reduction, with a highly signiﬁ cant reduction in 
ischaemic stroke (1427 vs 1751; RR 0·79, 95% CI 
0·74–0·85; p<0·0001; webappendix p 9) and a non-
signiﬁ cant excess of haemorrhagic stroke (257 vs 220; 
RR 1·12, 95% CI 0·93–1·35; p=0·2; webappendix p 10). 
The outcome of ﬁ rst stroke after randomisation was 
available from 24 of the 26 trials, with 728 (15%) of 
4948 ﬁ rst strokes classiﬁ ed as fatal and a further 256 
stroke deaths reported (253 after non-fatal ﬁ rst strokes 
and three in a trial9 without stroke incidence data). 
Overall, there was no signiﬁ cant eﬀ ect on mortality from 
Figure 3: Eﬀ ects on major vascular events per 1·0 mmol/L reduction in LDL cholesterol, by baseline 
prognostic factors 
Rate ratios (RRs) are plotted for each comparison of ﬁ rst event rates between treatment groups, and are weighted 
per 1·0 mmol/L LDL cholesterol (LDL-C) diﬀ erence at 1 year. Missing data are not plotted. RRs are shown with 
horizontal lines denoting 99% CIs or with open diamonds showing 95% CIs. CHD=coronary heart disease. 
GFR=glomerular ﬁ ltration rate.
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stroke (483 statin/more statin vs 501 control/less statin; 
RR 0·96, 95% CI 0·84–1·09; p=0·5), on mortality from 
ﬁ rst stroke (369 vs 359), or on mortality from ﬁ rst 
ischaemic (136 vs 124) or ﬁ rst haemorrhagic (94 vs 75) 
stroke. Likewise, there was no signiﬁ cant eﬀ ect on the 
incidence of ﬁ rst non-fatal haemorrhagic stroke 
(163 vs 145; RR 1·05, 99% CI 0·77–1·43; p=0·7). There 
was, however, a highly signiﬁ cant reduction in ﬁ rst non-
fatal ischaemic stroke (1291 vs 1627), corresponding to a 
23% (99% CI 15–30; p<0·0001) reduction per 1·0 mmol/L 
reduction in LDL cholesterol.
First major vascular events were reduced by about a ﬁ fth 
per 1·0 mmol/L LDL cholesterol reduction in each 
subgroup examined in the ﬁ ve trials of more versus less 
intensive statin therapy (webappendix p 11), in the 21 trials 
of statin versus control (webappendix p 12), and in all 
26 trials combined (ﬁ gure 3), even though the annual 
event rates in control groups diﬀ ered substantially 
according to participants’ medical history and other 
characteristics. In particular, there was a highly signiﬁ cant 
proportional risk reduction of 25% (99% CI 18–31; 
p<0·0001) per 1·0 mmol/L reduction in LDL cholesterol 
in participants with no previous history of vascular disease, 
as well as signiﬁ cant reductions of 17% (99% CI 10–24; 
p<0·0001) among women and of 16% (99% CI 3–27; 
p=0·002) in people older than 75 years at entry (ﬁ gure 3). 
Baseline LDL cholesterol concentrations were 
substantially higher in the trials of statin versus control 
(3·70 mmol/L on no statin) than in those of more versus 
less intensive therapy (2·53 mmol/L on the less intensive 
regimen), so the latter group provides most of the 
information about the eﬀ ects of reducing LDL cholesterol 
concentrations that were already low (eg, less than 
2·5 mmol/L; ﬁ gure 4). In these trials of more versus less 
statin, the RR per 1·0 mmol/L further reduction in LDL 
cholesterol did not depend on the baseline LDL cholesterol 
concentration (trend p=0·2; ﬁ gure 4), with signiﬁ cant 
reductions of 23% (99% CI 6–36; p=0·0005) in participants 
who had LDL cholesterol of 2·0–2·5 mmol/L reduced 
further and of 29% (99% CI 2–48; p=0·007) in those who 
had LDL cholesterol lower than 2·0 mmol/L (mean 
1·71 mmol/L) reduced further. Indeed, even among those 
reaching 1·8 mmol/L (70 mg/dL) or lower with a standard 
statin regimen, further reduction yielded deﬁ nite beneﬁ t 
(RR 0·63, 99% CI 0·41–0·95; p=0·004; not shown 
separately in ﬁ gure 4).
Some have suggested that HDL cholesterol 
concentrations might not be inversely associated with 
vascular disease risk when LDL cholesterol is reduced 
intensively42 (which would imply that the risk reduction 
with statin therapy is smaller in people with higher HDL 
cholesterol). But, this hypothesis was not supported by 
comparisons of the major vascular event risks in baseline 
HDL cholesterol subgroups (ﬁ gure 3; webappendix pp 11 
and 12). In particular, after adjustment for other risk 
factors, the risk ratio for upper versus lower tertiles of 
HDL cholesterol in participants allocated more intensive 
statin therapy (RR 0·81, 95% CI 0·74–0·89) was similar 
to that in those allocated less intensive therapy (RR 0·84, 
95% CI 0·77–0·92).
Death was recorded for 3593 participants in the ﬁ ve trials 
of more versus less intensive statin therapy and for 12 376 
in the 21 trials of statin versus control, yielding a total of 
15 969 deaths in all 26 trials. Overall, 9014 (56%) of these 
deaths were attributed to vascular causes (4168 coronary, 
3049 other cardiac, 984 stroke, 813 other vascular), 
5937 (37%) were attributed to non-vascular causes 
(3579 cancer, 461 respiratory, 254 trauma, and 1643 other), 
and 1018 (6%) had unknown causes (webappendix p 2). 
For each of these categories of death, the proportional 
reductions in risk per 1·0 mmol/L LDL cholesterol 
reduction did not diﬀ er between the two types of trial 
comparison (all heterogeneity p values >0·1). Taking all 
26 trials together, there was a proportional reduction in all-
cause mortality of 10% (95% CI 7–13; p<0·0001; ﬁ gure 5) 
per 1·0 mmol/L reduction in LDL cholesterol, which 
consisted of a highly signiﬁ cant reduction in vascular 
mortality of 14% (95% CI 10–18; p<0·0001) and a marginally 
signiﬁ cant reduction in mortality from unknown causes of 
13% (95% CI 1–24; p=0·04), with no apparent eﬀ ect on 
non-vascular mortality (RR 0·97, 95% CI 0·92–1·03; 
p=0·3). The reduction in vascular mortality was chieﬂ y 
attributable to signiﬁ cant reductions in deaths due to 
Figure 4: Eﬀ ects on major vascular events per 1·0 mmol/L reduction in LDL cholesterol, by baseline LDL 
cholesterol concentration on the less intensive or control regimen
Rate ratios (RRs) are plotted for each comparison of ﬁ rst event rates between treatment groups, and are weighted 
per 1·0 mmol/L LDL cholesterol (LDL-C) diﬀ erence at 1 year. Analyses were done with trial-speciﬁ c and subgroup-
speciﬁ c LDL weights for each baseline LDL cholesterol category. Missing data are not plotted. RRs are shown with 
horizontal lines denoting 99% CIs or with open diamonds showing 95% CIs. 
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coronary disease of 20% (99% CI 13–26; p<0·0001) and 
other cardiac causes of 11% (99% CI 2–19; p=0·002) per 
1·0 mmol/L, with no apparent eﬀ ects on deaths due to 
stroke (RR 0·96, 95% CI 0·84–1·09; p=0·5) or other 
vascular causes (RR 0·98, 99% CI 0·81–1·18; p=0·8). With 
respect to non-vascular mortality, there were no apparent 
eﬀ ects on deaths from cancer (RR 0·99, 99% CI 0·91–1·09), 
respiratory disease (RR 0·88, 99% CI 0·70–1·11), trauma 
(RR 0·98, 99% CI 0·70–1·38), or all other non-vascular 
causes (RR 0·96, 99% CI 0·83–1·10). There was no 
indication that reduction of LDL cholesterol in individuals 
with lower baseline concentrations increased non-vascular 
mortality (trend p=0·2).
First cancers after randomisation were recorded in 
2938 participants in the ﬁ ve trials of more versus less 
intensive statin therapy and in 7186 participants in the 
21 trials of statin versus control, yielding a total of 10 124 ﬁ rst 
cancers in all 26 trials (excluding cancers known to be 
recurrences of primary tumours diagnosed before 
randomisation, and non-melanoma skin cancers since 
they were not recorded routinely). In the ﬁ ve trials of more 
versus less intensive statin therapy, reduction of LDL 
cholesterol to a mean of about 2 mmol/L had no signiﬁ cant 
eﬀ ect on the incidence of cancer at all sites combined (RR 
1·02 per 1·0 mmol/L LDL cholesterol reduction, 95% CI 
0·89–1·18; p=0·8) or at any particular site (ﬁ gure 6 and 
webappendix p 13). Similarly, there was no signiﬁ cant 
eﬀ ect in the 21 trials of statin versus control and, taking all 
26 trials together, there was no evidence of an excess of 
cancer at all sites combined (RR 1·00 per 1·0 mmol/L LDL 
reduction, 95% CI 0·96–1·04; p=0·9) or at any particular 
site. There was also no indication that reduction of LDL 
cholesterol in individuals with lower baseline 
concentrations increased cancer incidence (indeed, if 
anything, the opposite pattern was observed; trend p=0·1). 
Only cases of myopathy that had progressed to 
rhabdomyolysis were sought from the individual trials. 
Overall, the observed excess of rhabdomyolysis was 
4 (SE 2) per 10 000 in the ﬁ ve trials of more versus less 
intensive statin therapy (14 vs six cases) compared with 
1 (SE 1) per 10 000 in the 21 trials of standard statin 
regimens versus control (14 vs nine cases). All of the 
excess (ten vs no cases) with more intensive therapy 
occurred in the two trials of 80 mg versus 20 mg 
simvastatin daily; these two trials have also reported 
deﬁ nite excesses in the incidence of myopathy with 
80 mg simvastatin daily.23,27
Discussion
The previous CTT meta-analysis of individual participant 
data from randomised trials showed that lowering of 
LDL cholesterol by about 1 mmol/L with standard statin 
regimens safely reduced the 5-year incidence of major 
coronary events, revascularisations, and ischaemic 
strokes by about a ﬁ fth.1 Several trials have since directly 
compared more intensive versus standard statin 
regimens.23–27 This updated meta-analysis has shown that 
additional reductions in LDL cholesterol (down to about 
1–2 mmol/L) with more intensive therapy further reduce 
the incidence of these major vascular events, that the 
relation between absolute LDL cholesterol reductions 
and proportional risk reductions is consistent between 
the trials of more versus less intensive statin therapy and 
those of standard statin regimens versus control, and 
that these further reductions in vascular risk can be 
achieved safely even in individuals with low LDL 
cholesterol concentrations.
Only two24,26 of the ﬁ ve trials that assessed the eﬀ ects of 
reducing LDL cholesterol more intensively23–27 produced 
separately signiﬁ cant results. But, adjustment for the 
absolute reduction in LDL cholesterol indicates that the 
results of these ﬁ ve trials are compatible with one 
another. Overall, a further reduction in LDL cholesterol 
of about 0·5 mmol/L was achieved, which reduced the 
residual risk of major vascular events by about a sixth, 
with separately signiﬁ cant reductions in coronary death 
or non-fatal myocardial infarction (p<0·0001), in 
coronary revascularisation procedures (p<0·0001), and 
in ischaemic stroke (p=0·005). Moreover, the proportional 
reduction in major vascular events per 1·0 mmol/L 
reduction in LDL cholesterol was similar to that observed 
in the updated meta-analysis of trials of statin versus 
control. The previous meta-analysis of statin versus 
control involved comparatively few major vascular events 
in participants with low LDL cholesterol before 
treatment,1 whereas the present meta-analyses provide 
Figure 5: Eﬀ ects on cause-speciﬁ c mortality per 1·0 mmol/L reduction in LDL cholesterol 
Rate ratios (RRs) are plotted for each comparison of ﬁ rst event rates between treatment groups and are weighted per 
1·0 mmol/L LDL cholesterol (LDL-C) diﬀ erence at 1 year. RRs are shown with horizontal lines denoting 99% CIs or with 
open diamonds showing 95% CIs. CHD=coronary heart disease. 
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good evidence of beneﬁ t, with no evidence of any hazard, 
even when LDL cholesterol concentrations lower than 
2 mmol/L are reduced further. Overall, there was a 
22% proportional reduction in the risk of major vascular 
events for each 1 mmol/L reduction in LDL cholesterol, 
which implies that, at least within the range of LDL 
cholesterol studied to date, a 2 mmol/L reduction would 
reduce the risk by about 40% (since the combination of 
risk ratios of 0·78×0·78 yields a risk ratio of about 0·6), 
and a 3 mmol/L reduction could reduce the risk by 
about 50%.
In the combined meta-analysis of trials of more versus 
less intensive statin therapy and of statin therapy versus 
control, coronary mortality was reduced by about a ﬁ fth 
per 1·0 mmol/L LDL cholesterol reduction, but the 
reduction in cardiac deaths that were not attributed to 
coronary disease was only about half as large. This ﬁ nding 
may reﬂ ect a relative lack of beneﬁ t from lowering of LDL 
cholesterol on cardiac deaths that are mediated by non-
occlusive mechanisms. For example, in the GISSI-HF31 
trial of rosuvastatin versus placebo in patients with heart 
failure (which was included in this meta-analysis), as well 
as in the similar CORONA32 trial (which was not), most 
cardiac deaths were non-occlusive and there were no 
signiﬁ cant reductions in cardiac mortality. Nor were there 
signiﬁ cant reductions in cardiac mortality in the two 
statin trials among patients with renal disease,29,30 in 
which only about half of cardiac deaths were deﬁ nitely 
due to coronary disease. By contrast, since most of the 
cardiac deaths that were coded as non-coronary in this 
meta-analysis occurred in patients with pre-existing 
coronary disease, some are likely to have been due to 
coronary occlusion (and, hence, reduced by statin 
therapy). These ﬁ ndings suggest that the absolute 
reduction in cardiac mortality produced by lowering of 
LDL cholesterol with statin therapy in a given population 
depends chieﬂ y on the absolute risk of death due to 
coronary occlusion.
There was no signiﬁ cant evidence in the meta-analysis 
of trials of more versus less intensive therapy that further 
lowering of LDL cholesterol (weighted mean of 
2·5 mmol/L reduced to 2·0 mmol/L) produced any 
adverse eﬀ ects, even in participants with baseline LDL 
cholesterol lower than 2·0 mmol/L. In one of those trials, 
the mean LDL cholesterol was reduced from 2·5 mmol/L 
to 1·9 mmol/L, and there was a non-signiﬁ cant excess of 
death from non-vascular or unknown causes (158 on 
80 mg atorvastatin vs 127 on 10 mg atorvastatin 
daily; p=0·06).25 But, that adverse trend was not supported 
by larger numbers of such deaths (590 [4·0%] vs 612 [4·1%]; 
RR 0·96, 95% CI 0·86–1·08; p=0·5) in the four other 
trials, or by an excess of any particular type of non-vascular 
mortality. Nor were there any adverse eﬀ ects on cancer 
incidence in the meta-analyses of more versus less 
intensive therapy or of statin versus control. If lowering of 
LDL cholesterol with statin therapy was carcinogenic then 
it might be expected to increase the incidence of cancer at 
some particular site, and previous reports from individual 
trials had raised such concerns about breast4 and 
gastrointestinal cancers;11 there was, however, no evidence 
in our analyses of an increase in cancer at these or any 
other sites.
Previous observational studies have generated the 
hypothesis that low cholesterol concentrations might be 
associated with an increased risk of intracerebral 
haemorrhage.18,43,44 The present meta-analyses, which 
included nearly 500 conﬁ rmed haemorrhagic strokes, 
showed that lowering of LDL cholesterol with statin 
therapy was associated with a non-signiﬁ cant excess 
(257 vs 220; p=0·2: webappendix p 10). In the SPARCL 
trial33 of atorvastatin versus placebo in patients with 
previous cerebrovascular disease (which was not available 
for this meta-analysis), there was a signiﬁ cant 20% 
proportional reduction in major vascular events (RR 0·80, 
95% CI 0·69–0·92; p=0·002). This result included a 
signiﬁ cant reduction in ischaemic stroke (218 vs 274; 
Figure 6: Eﬀ ects on site-speciﬁ c cancer incidence per 1·0 mmol/L reduction in LDL cholesterol 
Rate ratios (RRs) are plotted for each comparison of ﬁ rst event rates between treatment groups and are weighted 
per 1·0 mmol/L LDL cholesterol (LDL-C) diﬀ erence at 1 year. RRs are shown with horizontal lines denoting 99% CIs 
or with open diamonds showing 95% CIs. Analyses are of ﬁ rst cancers, subdivided by site: gastrointestinal 
(International Classiﬁ cation of Disease codes version 9 140–159); genitourinary (179–189); respiratory 
(160–163,165); female breast (174); haematological (200–208); melanoma (172); other/unknown site (other 
cancers with codes 140–172, 174–209, plus deaths with codes 173, 210–239). 
More vs less statin
Gastrointestinal
Genitourinary
Respiratory
Female breast
Haematological
Melanoma
Other/unknown
Any
Statin vs control
Gastrointestinal
Genitourinary
Respiratory
Female breast
Haematological
Melanoma
Other/unknown
Any
All trials combined
Gastrointestinal
Genitourinary
Respiratory
Female breast
Haematological
Melanoma
Other/unknown
Any
288 (0·3%)
480 (0·5%)
231 (0·3%)
73 (0·4%)
95 (0·1%)
56 (0·1%)
243 (0·3%)
1466 (1·6%)
878 (0·3%)
1116 (0·4%)
582 (0·2%)
194 (0·3%)
210 (0·1%)
103 (0·0%)
511 (0·2%)
3594 (1·4%)
1166 (0·3%)
1596 (0·5%)
813 (0·2%)
267 (0·3%)
305 (0·1%)
159 (0·0%)
754 (0·2%)
5060 (1·4%)
322 (0·4%)
496 (0·5%)
219 (0·2%)
54 (0·3%)
82 (0·1%)
42 (0·0%)
257 (0·3%)
1472 (1·6%)
872 (0·3%)
1149 (0·4%)
595 (0·2%)
187 (0·2%)
209 (0·1%)
100 (0·0%)
480 (0·2%)
3592 (1·4%)
1194 (0·3%)
1645 (0·5%)
814 (0·2%)
241 (0·3%)
291 (0·1%)
142 (0·0%)
737 (0·2%)
5064 (1·4%)
0·79 (0·52−1·20)
1·00 (0·72−1·38)
1·15 (0·70−1·90)
1·60 (0·66−3·87)
1·34 (0·61−2·98)
1·84 (0·64−5·29)
0·96 (0·63−1·46)
1·02 (0·89−1·18)
0·99 (0·88−1·11)
0·96 (0·87−1·06)
0·99 (0·86−1·14)
1·04 (0·80−1·34)
1·02 (0·81−1·28)
1·09 (0·78−1·51)
1·05 (0·89−1·25)
1·00 (0·95−1·04)
0·97 (0·87−1·09)
0·97 (0·88−1·06)
1·00 (0·88−1·15)
1·07 (0·84−1·38)
1·04 (0·84−1·30)
1·14 (0·83–1·56)
1·04 (0·89−1·21)
1·00 (0·96−1·04)
99% or
95% CI
RR (CI) per 1 mmol/L reduction in LDL-CEvents (% per annum)
Statin/more Control/less
0·5 0·75 1 1·25 1·6
Control/less betterStatin/more better
Articles
www.thelancet.com   Vol 376   November 13, 2010 1679
p=0·008), but a signiﬁ cant excess of haemorrhagic stroke 
(55 vs 33; p=0·02). In the two other trials of statin versus 
control that were not available for the meta-analysis, 
there were 15 versus nine haemorrhagic strokes in 
CORONA,32 but the numbers were not available for 
GREACE.41 If the published data for haemorrhagic stroke 
from SPARCL and CORONA were combined with the 
present meta-analysis then the rate ratio would be 
1·21 (95% CI 1·05–1·41) per 1·0 mmol/L LDL cholesterol 
reduction. Although this result is signiﬁ cant (p=0·01), 
the absolute size of the potential hazard would be about 
50 times smaller (perhaps a few extra haemorrhagic 
strokes annually per 10 000 treated) than the deﬁ nite 
absolute beneﬁ ts (a few hundred occlusive events avoided 
annually per 10 000 treated) for patients who are at high 
risk of occlusive vascular events.
In these meta-analyses, the size of the proportional 
reduction in major vascular events is directly proportional 
to the absolute LDL reduction that is achieved, with 
further beneﬁ t from more intensive statin therapy, even 
if LDL cholesterol is already lower than 2·0 mmol/L. 
Each 1 mmol/L LDL cholesterol reduction reduces the 
risk of occlusive vascular events by about a ﬁ fth, 
irrespective of baseline cholesterol concentration, which 
implies that a 2–3 mmol/L reduction would reduce risk 
by about 40–50%. These ﬁ ndings suggest that the primary 
goal for patients at high risk of occlusive vascular events 
should be to achieve the largest LDL cholesterol reduction 
possible without materially increasing myopathy risk. 
Current therapeutic guidelines tend to emphasise the 
need to reach a particular LDL cholesterol target—for 
example, US National Cholesterol Education Program 
guidelines suggest that the objective in high-risk patients 
should generally be to reduce LDL cholesterol to below 
100 mg/dL (2·6 mmol/L) or, optionally, for very high risk 
patients, to below 70 mg/dL (1·8 mmol/L).45 By contrast, 
our results suggest that lowering of LDL cholesterol 
further in high-risk patients who achieve such targets 
would produce additional beneﬁ ts, without an increased 
risk of cancer or non-vascular mortality. Guidelines have 
proposed that high doses of generic statins (eg, 80 mg 
simvastatin daily) be used to achieve these beneﬁ ts,46 but 
such regimens may be associated with higher risk of 
myopathy.27 Instead, these beneﬁ ts may be achieved more 
safely with newer, more potent statins (eg, 80 mg 
atorvastatin or 20 mg rosuvastatin daily) and, potentially, 
by combination of standard doses of generic statins (eg, 
40 mg simvastatin or pravastatin daily) with other LDL-
cholesterol-lowering therapies.47–49 
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